Zoetis Inc. $ZTS Shares Bought by Wealthfront Advisers LLC

Wealthfront Advisers LLC grew its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 178.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 42,240 shares of the company’s stock after buying an additional 27,046 shares during the quarter. Wealthfront Advisers LLC’s holdings in Zoetis were worth $4,993,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Zoetis by 12.9% during the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after acquiring an additional 5,474,210 shares during the last quarter. J. Stern & Co. LLP increased its position in shares of Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after purchasing an additional 23,877,416 shares during the last quarter. State Street Corp raised its stake in shares of Zoetis by 0.8% in the 4th quarter. State Street Corp now owns 19,796,891 shares of the company’s stock valued at $2,490,845,000 after purchasing an additional 149,382 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Zoetis by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock worth $1,420,294,000 after purchasing an additional 189,235 shares during the last quarter. Finally, Norges Bank acquired a new position in Zoetis in the fourth quarter worth about $734,425,000. Institutional investors own 92.80% of the company’s stock.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis was named as title sponsor of PawsitiveIntelligence.ai, adding a small brand-visibility and industry-partnership angle. Pawsitive Holdings Announces Zoetis as Title Sponsor of PawsitiveIntelligence.ai
• Positive Sentiment: Some commentary argued Zoetis offers an attractive risk-reward setup, suggesting a more constructive long-term view despite recent volatility. Zoetis: An Attractive Risk-Reward Opportunity
• Neutral Sentiment: Zoetis’ upcoming second-quarter earnings report is getting attention, with analysts expecting modest growth and investors watching for updated guidance and commentary on diagnostics demand. Zoetis Earnings Preview: What to Expect
• Neutral Sentiment: Zoetis announced it will acquire VitalRADS, a veterinary teleradiology platform, which could support its diagnostics strategy and AI-enabled offerings. Zoetis Gains as VitalRADS Deal Boosts Diagnostics Narrative
• Negative Sentiment: Multiple law firms issued reminders and investor alerts tied to a securities class action against Zoetis, reinforcing concerns about litigation risk and possible reputational damage. Deadline Alert for CALX, AVAV, ZTS, LCID
• Negative Sentiment: Additional class-action notices specifically target Zoetis shareholders, underscoring that the lawsuit remains an active overhang for the stock. ZTS Shareholder Alert
• Negative Sentiment: The legal backdrop follows earlier reports alleging investor harm and reminding shareholders of the same July 27 deadline, keeping sentiment cautious. Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Insider Buying and Selling at Zoetis

In other news, Director Paul Bisaro purchased 2,000 shares of the stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the transaction, the director owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Frank A. Damelio acquired 6,650 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director owned 21,458 shares in the company, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders have purchased 11,650 shares of company stock worth $886,384. 0.22% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts have issued reports on ZTS shares. Weiss Ratings cut Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. Citigroup dropped their price target on Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Morgan Stanley reaffirmed an “overweight” rating and issued a $115.00 price objective on shares of Zoetis in a report on Friday, May 15th. Stifel Nicolaus dropped their target price on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a report on Friday, June 26th. Finally, Wall Street Zen downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $120.83.

Zoetis Stock Down 0.6%

NYSE:ZTS opened at $76.44 on Friday. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The stock has a 50 day moving average of $77.33 and a 200-day moving average of $106.03. The firm has a market capitalization of $32.05 billion, a PE ratio of 12.68, a price-to-earnings-growth ratio of 1.19 and a beta of 0.75. Zoetis Inc. has a 52 week low of $71.47 and a 52 week high of $160.48.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The company had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same period last year, the business posted $1.48 EPS. The company’s revenue for the quarter was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Analysts predict that Zoetis Inc. will post 6.87 EPS for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.8%. Zoetis’s dividend payout ratio (DPR) is currently 35.16%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.